Valproate semisodium

From Wikipedia, the free encyclopedia - View original article

Valproate semisodium
Valproate-semisodium2DACS.svg
Systematic (IUPAC) name
sodium 2-propylpentanoic acid 2-propylpentanoate
Clinical data
Trade namesDepakote
AHFS/Drugs.com
MedlinePlusa682412
Pregnancy cat.D, X (US; depends on its indication)
Legal status-only (CA) POM (UK) -only (US)
RoutesOral
Pharmacokinetic data
Protein binding10-18.5% (dose-dependent)
MetabolismHepatic (30-50% via glucuronidation; 40% via β-oxidation & 15-20% via other oxidative pathways)
Half-life9-16 hours (dose-dependent)
ExcretionRenal (<3% unchanged)
Identifiers
ATC code?
PubChemCID 23663956
Chemical data
FormulaC16H31NaO4 
 
Jump to: navigation, search
Main article: Valproic acid
Valproate semisodium
Valproate-semisodium2DACS.svg
Systematic (IUPAC) name
sodium 2-propylpentanoic acid 2-propylpentanoate
Clinical data
Trade namesDepakote
AHFS/Drugs.com
MedlinePlusa682412
Pregnancy cat.D, X (US; depends on its indication)
Legal status-only (CA) POM (UK) -only (US)
RoutesOral
Pharmacokinetic data
Protein binding10-18.5% (dose-dependent)
MetabolismHepatic (30-50% via glucuronidation; 40% via β-oxidation & 15-20% via other oxidative pathways)
Half-life9-16 hours (dose-dependent)
ExcretionRenal (<3% unchanged)
Identifiers
ATC code?
PubChemCID 23663956
Chemical data
FormulaC16H31NaO4 

Valproate semisodium (INN, BAN) or divalproex sodium (USAN) consists of a compound of sodium valproate and valproic acid in a 1:1 molar relationship in an enteric coated form.[1] Its chief use in medicine is as a treatment for bipolar disorder, epilepsy and in the prevention of migraines.[2]

Medical uses[edit]

Main article: Valproic acid § Uses

It is used in the treatment of migraines, bipolar disorder and epilepsy.[2][3][4]

Adverse effects[edit]

Adverse effects by frequency:[2][3][4]
Very common (>10% frequency):

  • Nausea
  • Tremor

Common (1-10% frequency):

Uncommon (0.01-0.1% frequency):

Rare (<0.01% frequency):

Rare cases of lethargy occasionally progressing to stupor, sometimes with associated hallucinations or convulsions have been reported. Encephalopathy and coma have very rarely been observed. These cases are most often seen in association with other factors such as rapid dose escalations or withdrawal from other medications. They have usually been reversible on withdrawal of treatment or reduction of dosage. These cases most commonly occur in the paediatric population. Weight gain should be monitored closely as there is a potential link between weight gain and polycystic ovary syndrome.

Contraindications[edit]

Contraindications:[2]

Interactions[edit]

Drug interactions include:[2][3][4]

Branded formulations[edit]

In the United States, generic versions of valproate semisodium became available on July 29, 2008.[5]

References[edit]

  1. ^ "Valproate". Martindale: The Complete Drug Reference (Pharmaceutical Press). 17 October 2013. Retrieved 18 January 2014. 
  2. ^ a b c d e "Depakote 250mg Tablets - Summary of Product Characteristics". electronic Medicines Compendium. Sanofi. 28 November 2013. Retrieved 18 January 2014. 
  3. ^ a b c "DEPAKOTE (divalproex sodium) tablet, delayed release [AbbVie Inc.]". DailyMed. AbbVie Inc. September 2013. Retrieved 18 January 2014. 
  4. ^ a b c "Depakote (divalproex sodium) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 18 January 2014. 
  5. ^ http://fdanews.com/newsletter/article?issueId=11836&articleId=109236

External links[edit]